Understanding COVID-19 vaccine hesitancy and resistance: another challenge in cancer patients
Introduction We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient’s choice. Methods We conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in...
Saved in:
| Published in | Supportive care in cancer Vol. 30; no. 1; pp. 289 - 293 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.01.2022
Springer Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0941-4355 1433-7339 1433-7339 |
| DOI | 10.1007/s00520-021-06419-y |
Cover
| Abstract | Introduction
We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient’s choice.
Methods
We conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in 3 oncology cancer centers in Tunisia between February-May 2021. Logistic regression was used to evaluate odds ratio predicting patient’s intentions toward the vaccine.
Results
Acceptance rate was 50.5%, 28.3% (
n
= 93) reported to definitely refuse the vaccine and 21.2% (
n
= 70) did not make their decision yet. High educational level, history of comorbidities, history of influenza vaccination in the current season, and patient’s opinion about the severity of COVID-19 did not predict vaccine resistance. However, patients who think that the vaccine may interfere with treatment efficacy (OR = 7.28, 95%CI [2.5–12.32]), or may impact cancer outcome (OR = 6.14, 95%CI [2.27–16.7]), were significantly more likely to refuse the vaccine. Patients who disagree that the vaccine is a major weapon against the pandemic (OR = 6.07, 95%CI [2.34–9.52]) or that it could reduce the virus transmission (OR = 7.34, 95%CI [4.22–11.81]) were also significantly more likely to reject the vaccination. Safety concerns were also significant predictive factors (OR = 7.9, 95%CI [4.10–11.27]. Confidence level in the authorities played a significant role in patient’s acceptance of the vaccine, indeed patients who are not registered (OR = 5.9, 95%CI [1.58–8.7]) or not informed about the Tunisian national vaccination platform EVAX (OR = 5.51, 95%CI [2.1–7.9]) were more likely to be against the vaccine.
Conclusion
Cancer patient’s education about the impact of the vaccine on their disease and on the COVID-19 is needed. Governments should build strategies to gain more population confidence. |
|---|---|
| AbstractList | We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient's choice. We conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in 3 oncology cancer centers in Tunisia between February-May 2021. Logistic regression was used to evaluate odds ratio predicting patient's intentions toward the vaccine. Acceptance rate was 50.5%, 28.3% (n = 93) reported to definitely refuse the vaccine and 21.2% (n = 70) did not make their decision yet. High educational level, history of comorbidities, history of influenza vaccination in the current season, and patient's opinion about the severity of COVID-19 did not predict vaccine resistance. However, patients who think that the vaccine may interfere with treatment efficacy (OR = 7.28, 95%CI [2.5-12.32]), or may impact cancer outcome (OR = 6.14, 95%CI [2.27-16.7]), were significantly more likely to refuse the vaccine. Patients who disagree that the vaccine is a major weapon against the pandemic (OR = 6.07, 95%CI [2.34-9.52]) or that it could reduce the virus transmission (OR = 7.34, 95%CI [4.22-11.81]) were also significantly more likely to reject the vaccination. Safety concerns were also significant predictive factors (OR = 7.9, 95%CI [4.10-11.27]. Confidence level in the authorities played a significant role in patient's acceptance of the vaccine, indeed patients who are not registered (OR = 5.9, 95%CI [1.58-8.7]) or not informed about the Tunisian national vaccination platform EVAX (OR = 5.51, 95%CI [2.1-7.9]) were more likely to be against the vaccine. Cancer patient's education about the impact of the vaccine on their disease and on the COVID-19 is needed. Governments should build strategies to gain more population confidence. Introduction We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient's choice. Methods We conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in 3 oncology cancer centers in Tunisia between February-May 2021. Logistic regression was used to evaluate odds ratio predicting patient's intentions toward the vaccine. Results Acceptance rate was 50.5%, 28.3% (n = 93) reported to definitely refuse the vaccine and 21.2% (n = 70) did not make their decision yet. High educational level, history of comorbidities, history of influenza vaccination in the current season, and patient's opinion about the severity of COVID-19 did not predict vaccine resistance. However, patients who think that the vaccine may interfere with treatment efficacy (OR = 7.28, 95%CI [2.5-12.32]), or may impact cancer outcome (OR = 6.14, 95%CI [2.27-16.7]), were significantly more likely to refuse the vaccine. Patients who disagree that the vaccine is a major weapon against the pandemic (OR = 6.07, 95%CI [2.34-9.52]) or that it could reduce the virus transmission (OR = 7.34, 95%CI [4.22-11.81]) were also significantly more likely to reject the vaccination. Safety concerns were also significant predictive factors (OR = 7.9, 95%CI [4.10-11.27]. Confidence level in the authorities played a significant role in patient's acceptance of the vaccine, indeed patients who are not registered (OR = 5.9, 95%CI [1.58-8.7]) or not informed about the Tunisian national vaccination platform EVAX (OR = 5.51, 95%CI [2.1-7.9]) were more likely to be against the vaccine. Conclusion Cancer patient's education about the impact of the vaccine on their disease and on the COVID-19 is needed. Governments should build strategies to gain more population confidence. IntroductionWe aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient’s choice.MethodsWe conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in 3 oncology cancer centers in Tunisia between February-May 2021. Logistic regression was used to evaluate odds ratio predicting patient’s intentions toward the vaccine.ResultsAcceptance rate was 50.5%, 28.3% (n = 93) reported to definitely refuse the vaccine and 21.2% (n = 70) did not make their decision yet. High educational level, history of comorbidities, history of influenza vaccination in the current season, and patient’s opinion about the severity of COVID-19 did not predict vaccine resistance. However, patients who think that the vaccine may interfere with treatment efficacy (OR = 7.28, 95%CI [2.5–12.32]), or may impact cancer outcome (OR = 6.14, 95%CI [2.27–16.7]), were significantly more likely to refuse the vaccine. Patients who disagree that the vaccine is a major weapon against the pandemic (OR = 6.07, 95%CI [2.34–9.52]) or that it could reduce the virus transmission (OR = 7.34, 95%CI [4.22–11.81]) were also significantly more likely to reject the vaccination. Safety concerns were also significant predictive factors (OR = 7.9, 95%CI [4.10–11.27]. Confidence level in the authorities played a significant role in patient’s acceptance of the vaccine, indeed patients who are not registered (OR = 5.9, 95%CI [1.58–8.7]) or not informed about the Tunisian national vaccination platform EVAX (OR = 5.51, 95%CI [2.1–7.9]) were more likely to be against the vaccine.ConclusionCancer patient’s education about the impact of the vaccine on their disease and on the COVID-19 is needed. Governments should build strategies to gain more population confidence. Introduction We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient’s choice. Methods We conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in 3 oncology cancer centers in Tunisia between February-May 2021. Logistic regression was used to evaluate odds ratio predicting patient’s intentions toward the vaccine. Results Acceptance rate was 50.5%, 28.3% ( n = 93) reported to definitely refuse the vaccine and 21.2% ( n = 70) did not make their decision yet. High educational level, history of comorbidities, history of influenza vaccination in the current season, and patient’s opinion about the severity of COVID-19 did not predict vaccine resistance. However, patients who think that the vaccine may interfere with treatment efficacy (OR = 7.28, 95%CI [2.5–12.32]), or may impact cancer outcome (OR = 6.14, 95%CI [2.27–16.7]), were significantly more likely to refuse the vaccine. Patients who disagree that the vaccine is a major weapon against the pandemic (OR = 6.07, 95%CI [2.34–9.52]) or that it could reduce the virus transmission (OR = 7.34, 95%CI [4.22–11.81]) were also significantly more likely to reject the vaccination. Safety concerns were also significant predictive factors (OR = 7.9, 95%CI [4.10–11.27]. Confidence level in the authorities played a significant role in patient’s acceptance of the vaccine, indeed patients who are not registered (OR = 5.9, 95%CI [1.58–8.7]) or not informed about the Tunisian national vaccination platform EVAX (OR = 5.51, 95%CI [2.1–7.9]) were more likely to be against the vaccine. Conclusion Cancer patient’s education about the impact of the vaccine on their disease and on the COVID-19 is needed. Governments should build strategies to gain more population confidence. We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient's choice. We conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in 3 oncology cancer centers in Tunisia between February-May 2021. Logistic regression was used to evaluate odds ratio predicting patient's intentions toward the vaccine. Acceptance rate was 50.5%, 28.3% (n = 93) reported to definitely refuse the vaccine and 21.2% (n = 70) did not make their decision yet. High educational level, history of comorbidities, history of influenza vaccination in the current season, and patient's opinion about the severity of COVID-19 did not predict vaccine resistance. However, patients who think that the vaccine may interfere with treatment efficacy (OR = 7.28, 95%CI [2.5-12.32]), or may impact cancer outcome (OR = 6.14, 95%CI [2.27-16.7]), were significantly more likely to refuse the vaccine. Patients who disagree that the vaccine is a major weapon against the pandemic (OR = 6.07, 95%CI [2.34-9.52]) or that it could reduce the virus transmission (OR = 7.34, 95%CI [4.22-11.81]) were also significantly more likely to reject the vaccination. Safety concerns were also significant predictive factors (OR = 7.9, 95%CI [4.10-11.27]. Confidence level in the authorities played a significant role in patient's acceptance of the vaccine, indeed patients who are not registered (OR = 5.9, 95%CI [1.58-8.7]) or not informed about the Tunisian national vaccination platform EVAX (OR = 5.51, 95%CI [2.1-7.9]) were more likely to be against the vaccine. Cancer patient's education about the impact of the vaccine on their disease and on the COVID-19 is needed. Governments should build strategies to gain more population confidence. We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient's choice.INTRODUCTIONWe aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient's choice.We conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in 3 oncology cancer centers in Tunisia between February-May 2021. Logistic regression was used to evaluate odds ratio predicting patient's intentions toward the vaccine.METHODSWe conducted a cross-sectional survey with a self-administered questionnaire delivered to 329 cancer patients in 3 oncology cancer centers in Tunisia between February-May 2021. Logistic regression was used to evaluate odds ratio predicting patient's intentions toward the vaccine.Acceptance rate was 50.5%, 28.3% (n = 93) reported to definitely refuse the vaccine and 21.2% (n = 70) did not make their decision yet. High educational level, history of comorbidities, history of influenza vaccination in the current season, and patient's opinion about the severity of COVID-19 did not predict vaccine resistance. However, patients who think that the vaccine may interfere with treatment efficacy (OR = 7.28, 95%CI [2.5-12.32]), or may impact cancer outcome (OR = 6.14, 95%CI [2.27-16.7]), were significantly more likely to refuse the vaccine. Patients who disagree that the vaccine is a major weapon against the pandemic (OR = 6.07, 95%CI [2.34-9.52]) or that it could reduce the virus transmission (OR = 7.34, 95%CI [4.22-11.81]) were also significantly more likely to reject the vaccination. Safety concerns were also significant predictive factors (OR = 7.9, 95%CI [4.10-11.27]. Confidence level in the authorities played a significant role in patient's acceptance of the vaccine, indeed patients who are not registered (OR = 5.9, 95%CI [1.58-8.7]) or not informed about the Tunisian national vaccination platform EVAX (OR = 5.51, 95%CI [2.1-7.9]) were more likely to be against the vaccine.RESULTSAcceptance rate was 50.5%, 28.3% (n = 93) reported to definitely refuse the vaccine and 21.2% (n = 70) did not make their decision yet. High educational level, history of comorbidities, history of influenza vaccination in the current season, and patient's opinion about the severity of COVID-19 did not predict vaccine resistance. However, patients who think that the vaccine may interfere with treatment efficacy (OR = 7.28, 95%CI [2.5-12.32]), or may impact cancer outcome (OR = 6.14, 95%CI [2.27-16.7]), were significantly more likely to refuse the vaccine. Patients who disagree that the vaccine is a major weapon against the pandemic (OR = 6.07, 95%CI [2.34-9.52]) or that it could reduce the virus transmission (OR = 7.34, 95%CI [4.22-11.81]) were also significantly more likely to reject the vaccination. Safety concerns were also significant predictive factors (OR = 7.9, 95%CI [4.10-11.27]. Confidence level in the authorities played a significant role in patient's acceptance of the vaccine, indeed patients who are not registered (OR = 5.9, 95%CI [1.58-8.7]) or not informed about the Tunisian national vaccination platform EVAX (OR = 5.51, 95%CI [2.1-7.9]) were more likely to be against the vaccine.Cancer patient's education about the impact of the vaccine on their disease and on the COVID-19 is needed. Governments should build strategies to gain more population confidence.CONCLUSIONCancer patient's education about the impact of the vaccine on their disease and on the COVID-19 is needed. Governments should build strategies to gain more population confidence. |
| Audience | Academic |
| Author | Mejri, Nesrine Boussen, Hamouda Berrazega, Yosra Kochbati, Lotfi Ouertani, Emna Rachdi, Haifa Bohli, Mariem |
| Author_xml | – sequence: 1 givenname: Nesrine orcidid: 0000-0001-7647-5027 surname: Mejri fullname: Mejri, Nesrine email: nesrinemejriturki2@gmail.com organization: Medical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University Tunis El Manar – sequence: 2 givenname: Yosra surname: Berrazega fullname: Berrazega, Yosra organization: Medical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University Tunis El Manar – sequence: 3 givenname: Emna surname: Ouertani fullname: Ouertani, Emna organization: Medical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University Tunis El Manar – sequence: 4 givenname: Haifa surname: Rachdi fullname: Rachdi, Haifa organization: Medical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University Tunis El Manar – sequence: 5 givenname: Mariem surname: Bohli fullname: Bohli, Mariem organization: Radiation Therapy Department, Abderahmen Mami Hospital, Faculty of Medicine, University Tunis El Manar – sequence: 6 givenname: Lotfi surname: Kochbati fullname: Kochbati, Lotfi organization: Radiation Therapy Department, Abderahmen Mami Hospital, Faculty of Medicine, University Tunis El Manar – sequence: 7 givenname: Hamouda surname: Boussen fullname: Boussen, Hamouda organization: Medical Oncology Department, Abderrahmane Mami Hospital, Faculty of Medicine, University Tunis El Manar, Medical Oncology, Clinic Taoufik |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34279721$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kk1vEzEQhi1URNPCH-CAVuLCZYu_7eWAVAUKlSr1Qrkhy-udTVxtvMHeVMq_Z9KUllao8sGy53lnNDPvETlIYwJC3jJ6wig1HwulitOaclZTLVlTb1-QGZNC1EaI5oDMaCNZLYVSh-SolGtKmTGKvyKHQnLTGM5m5NdV6iCXyacupkU1v_x5_qVmTXXjQ4gJqiWUiMGwrZCoMr52bIBP-B6nJeQqLP0wQFpAFVMVdrFcrf0UIU3lNXnZ-6HAm7v7mFydff0x_15fXH47n59e1EFJNtWh663s2sZqaGkwypseWtYqK0FbQ73gEkwbvAYvtdFt6BlXDRfQasVM6MUx-bzPu960K-gC1s5-cOscVz5v3eijexxJcekW442z3OrGGkzw4S5BHn9voExuFUuAYfAJxk1xXCnBheKKIvr-CXo9bnLC9hzXVDaWG6MfqIUfwMXUj1g37JK6U22lUhIbQ-rkPxSeDlYx4Lb7iP-PBO_-bfS-w78LRYDvgZDHUjL09wijbucat3eNQ9e4W9e4LYrsE1HApU9x3A0rDs9LxV5asA6aID9M4xnVH85m1mo |
| CitedBy_id | crossref_primary_10_1016_j_vaccine_2022_09_063 crossref_primary_10_3390_cancers14225630 crossref_primary_10_3390_vaccines10091373 crossref_primary_10_1007_s10900_022_01174_5 crossref_primary_10_2217_fon_2021_1015 crossref_primary_10_1016_j_soh_2023_100048 crossref_primary_10_3390_vaccines11111637 crossref_primary_10_3390_pathogens11050567 crossref_primary_10_1016_j_joim_2021_10_004 crossref_primary_10_61186_rabms_9_4_200 crossref_primary_10_1080_07357907_2023_2233624 crossref_primary_10_1590_0102_311xpt041423 crossref_primary_10_3390_vaccines10091530 crossref_primary_10_1016_j_ijid_2023_04_397 crossref_primary_10_7189_jogh_14_05010 crossref_primary_10_1007_s00520_022_07238_5 crossref_primary_10_1016_j_esmoop_2023_101566 crossref_primary_10_3390_vaccines12101163 crossref_primary_10_1183_23120541_00590_2023 crossref_primary_10_7759_cureus_38618 crossref_primary_10_1590_0102_311xen041423 crossref_primary_10_1371_journal_pone_0290792 crossref_primary_10_3389_fonc_2023_1281994 crossref_primary_10_1089_jayao_2022_0113 crossref_primary_10_1080_10810730_2023_2168800 crossref_primary_10_3390_vaccines10111777 crossref_primary_10_1200_OP_22_00338 crossref_primary_10_1038_s41571_022_00610_8 crossref_primary_10_1186_s12889_023_15386_4 crossref_primary_10_3389_fpsyg_2022_923316 crossref_primary_10_1007_s00520_023_07667_w crossref_primary_10_1007_s00432_022_03961_y crossref_primary_10_1186_s12879_023_08478_4 crossref_primary_10_1089_mab_2021_0060 crossref_primary_10_3389_fpubh_2024_1382849 crossref_primary_10_1016_S1470_2045_22_00273_X crossref_primary_10_1371_journal_pone_0279809 crossref_primary_10_1159_000536548 crossref_primary_10_3390_vaccines11030530 crossref_primary_10_1016_j_jvacx_2022_100243 crossref_primary_10_1111_ajco_13808 crossref_primary_10_1016_j_puhe_2022_09_001 crossref_primary_10_1016_j_japh_2024_102184 crossref_primary_10_1016_j_pec_2023_107680 crossref_primary_10_1080_21645515_2022_2031775 crossref_primary_10_1186_s12910_022_00827_3 crossref_primary_10_1016_j_heliyon_2024_e26869 crossref_primary_10_1186_s12982_025_00479_9 crossref_primary_10_3389_fonc_2022_1014786 crossref_primary_10_3389_fpubh_2023_1236376 crossref_primary_10_1080_21645515_2022_2094149 crossref_primary_10_1080_08964289_2022_2082358 crossref_primary_10_2196_29872 crossref_primary_10_1080_21645515_2022_2043719 crossref_primary_10_1158_1055_9965_EPI_22_0607 |
| Cites_doi | 10.15585/mmwr.mm6949e1 10.3390/bs11040056 10.1158/2159-8290.CD-20-1817 10.1016/j.eclinm.2020.100495 10.1001/jamanetworkopen.2020.25594 10.1001/jamahealthforum.2021.0264 10.1159/000514636 10.1371/journal.pone.0250555 10.1007/s00296-021-04841-3 10.1016/S1470-2045(20)30442-3 10.1016/S0140-6736(20)31558-0 10.1016/j.annonc.2021.01.066 10.1097/COC.0000000000000712 10.1016/j.ypmed.2018.01.006 10.1016/S1470-2045(20)30096-6 10.3390/vaccines9040302 10.1056/NEJMp2033970 10.1016/j.bbi.2021.03.008 10.1016/j.fct.2021.112333 10.1038/s41591-020-1124-9 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. COPYRIGHT 2022 Springer The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 – notice: 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. – notice: COPYRIGHT 2022 Springer – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0-V 3V. 7RV 7X7 7XB 88E 88J 8AO 8FI 8FJ 8FK ABUWG AFKRA ALSLI AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ HEHIP K9. KB0 M0S M1P M2R M2S NAPCQ PHGZM PHGZT PJZUB PKEHL POGQB PPXIY PQEST PQQKQ PQUKI PRINS PRQQA Q9U 7X8 5PM |
| DOI | 10.1007/s00520-021-06419-y |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Social Sciences Premium Collection【Remote access available】 ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Social Science Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Social Science Premium Collection ProQuest Central Essentials ProQuest Central Database Suite (ProQuest) ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Sociology Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni) Medical Database Social Science Database (Proquest) Proquest Sociology Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest Sociology & Social Sciences Collection ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Social Sciences ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Sociology & Social Sciences Collection ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Social Science Journals (Alumni Edition) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Sociology & Social Sciences Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Sociology Collection ProQuest Central (New) ProQuest Sociology ProQuest Medical Library (Alumni) Social Science Premium Collection ProQuest One Social Sciences ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Sociology Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Social Science Journals ProQuest Medical Library ProQuest Social Sciences Premium Collection ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Sociology & Social Sciences Collection MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Nursing |
| EISSN | 1433-7339 |
| EndPage | 293 |
| ExternalDocumentID | PMC8286987 A684554870 34279721 10_1007_s00520_021_06419_y |
| Genre | Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 0-V 04C 06C 06D 0R~ 0VY 123 1N0 1SB 2.D 203 28- 29Q 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5QI 5VS 67Z 6NX 6PF 78A 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADOJX ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALSLI ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARALO ARMRJ ASOEW ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BBWZM BDATZ BENPR BGNMA BKEYQ BMSDO BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS ECF ECT EIHBH EIOEI EJD EMOBN EN4 ESBYG EX3 F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HEHIP HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IAO IHE IHR IJ- IKXTQ IMOTQ INH INR ITC ITM IWAJR IXC IXE IZIGR IZQ I~X I~Z J-C J0Z J5H JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M2R M2S M4Y MA- N2Q N9A NAPCQ NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UDS UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOW YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZMTXR ZOVNA ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT ABRTQ CGR CUY CVF ECM EIF NPM PJZUB POGQB PPXIY PRQQA AEIIB PMFND 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c541t-cdf84db986eb0c75a7feb1b584e6870a324e7bca6ea4676bcf125923eb6517cf3 |
| IEDL.DBID | U2A |
| ISSN | 0941-4355 1433-7339 |
| IngestDate | Thu Aug 21 17:41:01 EDT 2025 Sun Aug 24 03:44:14 EDT 2025 Fri Jul 25 21:00:45 EDT 2025 Tue Jun 17 21:07:11 EDT 2025 Tue Jun 10 20:17:49 EDT 2025 Mon Jul 21 06:05:56 EDT 2025 Tue Jul 01 04:25:55 EDT 2025 Thu Apr 24 22:58:46 EDT 2025 Fri Feb 21 02:47:30 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | COVID-19 Hesitancy Vaccination Cancer |
| Language | English |
| License | 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-cdf84db986eb0c75a7feb1b584e6870a324e7bca6ea4676bcf125923eb6517cf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-7647-5027 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8286987 |
| PMID | 34279721 |
| PQID | 2604982776 |
| PQPubID | 326297 |
| PageCount | 5 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8286987 proquest_miscellaneous_2553235250 proquest_journals_2604982776 gale_infotracmisc_A684554870 gale_infotracacademiconefile_A684554870 pubmed_primary_34279721 crossref_primary_10_1007_s00520_021_06419_y crossref_citationtrail_10_1007_s00520_021_06419_y springer_journals_10_1007_s00520_021_06419_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-01 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Supportive care in cancer |
| PublicationTitleAbbrev | Support Care Cancer |
| PublicationTitleAlternate | Support Care Cancer |
| PublicationYear | 2022 |
| Publisher | Springer Berlin Heidelberg Springer Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer – name: Springer Nature B.V |
| References | Barrière, Gal, Hoch (CR8) 2021 Malik, McFadden, Elharake, Omer (CR13) 2020; 26 El-Elimat, AbuAlSamen, Almomani (CR16) 2021; 16 de Figueiredo, Simas, Karafillakis (CR7) 2020; 396 Kreps, Prasad, Brownstein (CR14) 2020; 3 Salwa, Robertson (CR22) 2021; 384 Latkin, Dayton, Miller (CR11) 2021; 11 Lazarus, Ratzan, Palayew (CR12) 2020 Dooling, McClung, Chamberland (CR6) 2020; 69 Al-Quteimat, Amer (CR1) 2020 Vallée, Fourn, Majerholc (CR19) 2021; 9 Lee, Cazier, Starkey (CR3) 2020; 21 Ribas, Sengupta, Locke (CR5) 2021; 11 Liang, Guan, Chen (CR2) 2020; 21 Press, Huisingh-Scheetz, Arora (CR10) 2021; 2 CR21 CR20 Alqudeimat, Alenezi, AlHajri (CR17) 2021 Sarathchandra, Navin, Largent, McCright (CR9) 2018; 109 Nile, Nile, Jalde, Kai (CR4) 2021; 154 Robertson, Reeve, Niedzwiedz (CR15) 2021; 94 Yurttas, Poyraz, Sut (CR18) 2021; 41 CA Latkin (6419_CR11) 2021; 11 T El-Elimat (6419_CR16) 2021; 16 VG Press (6419_CR10) 2021; 2 SH Nile (6419_CR4) 2021; 154 W Liang (6419_CR2) 2020; 21 Y Alqudeimat (6419_CR17) 2021 OM Al-Quteimat (6419_CR1) 2020 J Salwa (6419_CR22) 2021; 384 LYW Lee (6419_CR3) 2020; 21 B Yurttas (6419_CR18) 2021; 41 S Kreps (6419_CR14) 2020; 3 JV Lazarus (6419_CR12) 2020 A de Figueiredo (6419_CR7) 2020; 396 AA Malik (6419_CR13) 2020; 26 J Barrière (6419_CR8) 2021 6419_CR20 D Sarathchandra (6419_CR9) 2018; 109 6419_CR21 A Vallée (6419_CR19) 2021; 9 A Ribas (6419_CR5) 2021; 11 K Dooling (6419_CR6) 2020; 69 E Robertson (6419_CR15) 2021; 94 |
| References_xml | – ident: CR21 – volume: 69 start-page: 1857 issue: 49 year: 2020 end-page: 1859 ident: CR6 article-title: The advisory committee on immunization practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine — United States, 2020 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6949e1 – volume: 11 start-page: 56 issue: 4 year: 2021 ident: CR11 article-title: Behavioral and attitudinal correlates of trusted sources of COVID-19 vaccine Information in the US publication-title: Behav Sci doi: 10.3390/bs11040056 – volume: 11 start-page: 233 issue: 2 year: 2021 end-page: 236 ident: CR5 article-title: Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is limited publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-1817 – volume: 26 start-page: 100495 year: 2020 ident: CR13 article-title: Determinants of COVID-19 vaccine acceptance in the US publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2020.100495 – volume: 3 start-page: e2025594 issue: 10 year: 2020 end-page: e2025594 ident: CR14 article-title: Factors Associated With US adults’ likelihood of accepting COVID-19 vaccination publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.25594 – volume: 2 start-page: e210264 issue: 3 year: 2021 ident: CR10 article-title: Inequities in technology contribute to disparities in COVID-19 vaccine distribution publication-title: JAMA Health Forum doi: 10.1001/jamahealthforum.2021.0264 – year: 2021 ident: CR17 article-title: Acceptance of a COVID-19 vaccine and its related determinants among the general adult population in Kuwait publication-title: MPP doi: 10.1159/000514636 – volume: 16 start-page: e0250555 issue: 4 year: 2021 ident: CR16 article-title: Acceptance and attitudes toward COVID-19 vaccines: a cross-sectional study from Jordan publication-title: PLOS ONE doi: 10.1371/journal.pone.0250555 – volume: 41 start-page: 1105 issue: 6 year: 2021 end-page: 1114 ident: CR18 article-title: Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey publication-title: Rheumatol Int doi: 10.1007/s00296-021-04841-3 – volume: 21 start-page: 1309 issue: 10 year: 2020 end-page: 1316 ident: CR3 article-title: COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30442-3 – volume: 396 start-page: 898 issue: 10255 year: 2020 end-page: 908 ident: CR7 article-title: Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study publication-title: Lancet doi: 10.1016/S0140-6736(20)31558-0 – year: 2021 ident: CR8 article-title: Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.01.066 – year: 2020 ident: CR1 article-title: The impact of the COVID-19 pandemic on cancer patients publication-title: Am J Clin Oncol doi: 10.1097/COC.0000000000000712 – volume: 109 start-page: 1 year: 2018 end-page: 7 ident: CR9 article-title: A survey instrument for measuring vaccine acceptance publication-title: Prev Med doi: 10.1016/j.ypmed.2018.01.006 – volume: 21 start-page: 335 issue: 3 year: 2020 end-page: 337 ident: CR2 article-title: Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30096-6 – volume: 9 start-page: 302 issue: 4 year: 2021 ident: CR19 article-title: COVID-19 Vaccine hesitancy among French people living with HIV publication-title: Vaccines doi: 10.3390/vaccines9040302 – volume: 384 start-page: 1684 issue: 18 year: 2021 end-page: 1687 ident: CR22 article-title: Designing an independent public health agency publication-title: N Engl J Med doi: 10.1056/NEJMp2033970 – volume: 94 start-page: 41 year: 2021 end-page: 50 ident: CR15 article-title: Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2021.03.008 – volume: 154 start-page: 112333 year: 2021 ident: CR4 article-title: Recent advances in potential drug therapies combating COVID-19 and related coronaviruses-a perspective publication-title: Food Chem Toxicol doi: 10.1016/j.fct.2021.112333 – year: 2020 ident: CR12 article-title: A global survey of potential acceptance of a COVID-19 vaccine publication-title: Nat Med doi: 10.1038/s41591-020-1124-9 – ident: CR20 – volume: 21 start-page: 1309 issue: 10 year: 2020 ident: 6419_CR3 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30442-3 – volume: 109 start-page: 1 year: 2018 ident: 6419_CR9 publication-title: Prev Med doi: 10.1016/j.ypmed.2018.01.006 – volume: 69 start-page: 1857 issue: 49 year: 2020 ident: 6419_CR6 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm6949e1 – volume: 41 start-page: 1105 issue: 6 year: 2021 ident: 6419_CR18 publication-title: Rheumatol Int doi: 10.1007/s00296-021-04841-3 – volume: 9 start-page: 302 issue: 4 year: 2021 ident: 6419_CR19 publication-title: Vaccines doi: 10.3390/vaccines9040302 – year: 2021 ident: 6419_CR17 publication-title: MPP doi: 10.1159/000514636 – volume: 154 start-page: 112333 year: 2021 ident: 6419_CR4 publication-title: Food Chem Toxicol doi: 10.1016/j.fct.2021.112333 – year: 2020 ident: 6419_CR1 publication-title: Am J Clin Oncol doi: 10.1097/COC.0000000000000712 – volume: 21 start-page: 335 issue: 3 year: 2020 ident: 6419_CR2 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30096-6 – volume: 396 start-page: 898 issue: 10255 year: 2020 ident: 6419_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(20)31558-0 – volume: 2 start-page: e210264 issue: 3 year: 2021 ident: 6419_CR10 publication-title: JAMA Health Forum doi: 10.1001/jamahealthforum.2021.0264 – volume: 11 start-page: 233 issue: 2 year: 2021 ident: 6419_CR5 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-20-1817 – volume: 3 start-page: e2025594 issue: 10 year: 2020 ident: 6419_CR14 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.25594 – volume: 94 start-page: 41 year: 2021 ident: 6419_CR15 publication-title: Brain Behav Immun doi: 10.1016/j.bbi.2021.03.008 – volume: 11 start-page: 56 issue: 4 year: 2021 ident: 6419_CR11 publication-title: Behav Sci doi: 10.3390/bs11040056 – volume: 384 start-page: 1684 issue: 18 year: 2021 ident: 6419_CR22 publication-title: N Engl J Med doi: 10.1056/NEJMp2033970 – year: 2021 ident: 6419_CR8 publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.01.066 – volume: 16 start-page: e0250555 issue: 4 year: 2021 ident: 6419_CR16 publication-title: PLOS ONE doi: 10.1371/journal.pone.0250555 – year: 2020 ident: 6419_CR12 publication-title: Nat Med doi: 10.1038/s41591-020-1124-9 – volume: 26 start-page: 100495 year: 2020 ident: 6419_CR13 publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2020.100495 – ident: 6419_CR20 – ident: 6419_CR21 |
| SSID | ssj0017752 |
| Score | 2.5395188 |
| Snippet | Introduction
We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with... We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with the patient's... Introduction We aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with... IntroductionWe aimed to measure the acceptability towards the COVID-19 vaccination in cancer patients and to investigate determinant factors associated with... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 289 |
| SubjectTerms | Cancer Cancer patients Cancer vaccines Care and treatment Comorbidity Coronaviruses COVID-19 COVID-19 Vaccines Cross-Sectional Studies Disease transmission Humans Immunization Influenza Influenza Vaccines Medical research Medicine Medicine & Public Health Medicine, Experimental Neoplasms - therapy Nursing Nursing Research Oncology Original Original Article Pain Medicine Patient education Patients Rehabilitation Medicine SARS-CoV-2 Surveys Vaccination Vaccine hesitancy |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1La9wwEB7aFEovIX27SYsKhR5a0bUtS1YuJaQNaSHJpVv2UoQkyyRQvEl2U8i_z4xWduKF5rhobLSe1zfSPAA-WC0qFZTgtc4DF0KX3DpV8DJYxOOtbZSjQuGjY3k4FT9n1SwduC1SWmVvE6Ohbuaezsi_IO4Wui6Ukl_PLzhNjaLb1TRC4yE8iq3LUJ7VbAi4cqXixB2MYDBOQseaimZi6VxMAOGUoIBOOdf8euSY1s3zHf-0nju5doEa_dLBFmwmQMn2VhLwFB6E7hk8PkpX5s_hz_Ru-QrbP_n94xvPNftnPRGwUxoMQCaWIQXD4JsAJUrCLv6O1VnM9_NW2FnHPK1dstSOdfECpgfff-0f8jRTgftK5Evum7YWjdO1DG7iVWVVi9baIQwJElXXIr4Kynkrg0UTKp1vEQEhCAxOVrnybfkSNrp5F14DCw6xSxGCLqUXyrZ6olu6Fp6UvimtazPI-w9qfGo4TnMv_pqhVXJkgkEmmMgEc53Bp-GZ81W7jXupPxKfDOkivtnbVFKA-6OuVmZP1qKikGySwc6IEnXIj5d7TpukwwtzK3EZvB-W6UnKS-vC_AppqqosqKMsvuLVSjCGfZeiUNQbKQM1EpmBgDp7j1e6s9PY4Ztq-3WtMvjcC9fttv7_Od7c_y-24UlBtRvx_GgHNpaXV-EtIqqlexfV5gYQRBxR priority: 102 providerName: ProQuest |
| Title | Understanding COVID-19 vaccine hesitancy and resistance: another challenge in cancer patients |
| URI | https://link.springer.com/article/10.1007/s00520-021-06419-y https://www.ncbi.nlm.nih.gov/pubmed/34279721 https://www.proquest.com/docview/2604982776 https://www.proquest.com/docview/2553235250 https://pubmed.ncbi.nlm.nih.gov/PMC8286987 |
| Volume | 30 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR1di9QwcPDuUHwRPb-q5xJB8EED2zZtGt92z11P5VYRV9YHCUk25Q6kJ7d7wv17Z7JpvS4q-BTaTELoZL46XwDPjBKF9FLwSqWeC6FybqzMeO4N6uO1WUpLicLHs_JoLt4tikVMClu10e6tSzJw6i7ZLYRscAopQDGaKn65A3v4JiNynGejzncgZeizg3YLWkcoTmOqzJ_36ImjbaZ8RSptR0xuuU2DNJrehltRjWSjDd7vwDXf7MON4-go34fr8S_AXfg2v5q-wg4_fHn7mqeK_TSOQNkJNQYgFssQgqHxTQol3oRX-Byys5hr-62w04Y5mjtnsRzr6h7Mp5PPh0c89lTgrhDpmrtlXYmlVVXp7dDJwsgaubVFNcSXSLoG9SsvrTOlN8hCS-tq1IBQCfS2LFLp6vw-7DZnjX8IzFvUXTLvVV46IU2thqomt_Awd8vc2DqBtP202sWC49T34rvuSiUHdGhEhw7o0JcJvOjW_NiU2_gn9HPCmCZaxJ2diSkFeD6qaqVHZSUKMsmGCRz0IJGGXH-6xbmONLzSaOkJVWVSlgk87aZpJcWlNf7sAmGKIs-ooixu8WBzRbpz5yKTVBspAdm7PB0AVfbuzzSnJ6HCN-X2q0om8LK9Zr-P9ffP8ej_wB_DzYxyOcL_pAPYXZ9f-CeoYa3tAHbkQg5gbzQdj2c0vvn6foLjeDL7-GkQyO0XW4MiKQ |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NToK9IL4XGGAkEA9g0SROHCMhNPahlq0FoXXaCzK242iTUDrWDtR_ir-RuzTJ1krsbY-RL5bjO9-dc3e_A3hplEikl4JnKvRcCBVzY2XEY2_QHy9MLi0VCg-GaW8kPh8lRyvwt6mFobTKRidWijofO_pH_g79bqGySMr04-kvTl2jKLratNCYi8Wen_3BK9vkQ38b-fsqinZ3DrZ6vO4qwF0iwil3eZGJ3Kos9bbrZGJkgfrKoiH2KQqvQQ_DS-tM6g0qkdS6An0AdIO8TZNQuiLGeW_AqqCK1g6sftoZfv3Wxi2krHr84J0Jb2ZoyusynapYr0o54ZQSgW5AqPhswRQuG4RLFnE5W3MpZFtZwt07cLt2YdnmXObuwoov78HNQR2kvw_fR5cLZtjWl8P-Ng8V-20cEbBjakVASp0hBcPrPrmwKHvv8bmqB2Ou6fDCTkrmaOyM1QCwkwcwupb9fgidclz6dWDeorcUea_i1AlpCtVVBQWiu7HLY2OLAMJmQ7WrIc6p08ZP3YIzV0zQyARdMUHPAnjTvnM6B_i4kvo18UnT6ceZnamLGHB9hKOlN9NMJHQJ7AawsUCJp9YtDjec1rXWmOgLGQ_gRTtMb1ImXOnH50iTJHFEGLY4xaO5YLTrjkUkCY0pALkgMi0BYYkvjpQnxxWmOKEJqEwG8LYRrotl_X87Hl_9Fc_hVu9gsK_3-8O9J7AWUeVI9fdqAzrTs3P_FP25qX1WHyIGP6773P4DATJb_A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NIU28IL7JGGAkEA9grUmcOEZCaFqpVsYGDxT1BRnbcbRJUzrWDtR_jb-OOzfJ1krsbY-RL5bjO9_9Lr4PgJdGiUx6KXihYs-FUCk3ViY89QbxeGVKaSlR-OAw3xuJT-NsvAZ_21wYCqtsdWJQ1OXE0T_ybcTdQhWJlPl21YRFfO0PPpz-4tRBim5a23YaCxHZ9_M_6L5N3w_7yOtXSTL4-G13jzcdBrjLRDzjrqwKUVpV5N72nMyMrFB3WTTKPkdBNog2vLTO5N6gQsmtqxAPICTyNs9i6aoU570BN2WKqArPkhx3zl4sZej2g94T-mho1JuEnZC2F4JPOAVHICCIFZ8vGcVV03DJNq7Gba5c3gabOLgDtxswy3YW0ncX1nx9DzYOmuv6-_BjdDl1hu1--T7s81ix38YRATuipgSk3hlSMHT8CcyiFL7D55AZxlzb64Ud18zR2BlrSsFOH8DoWnb7IazXk9o_BuYt4qbEe5XmTkhTqZ6q6Eq6l7oyNbaKIG43VLum2Dn13DjRXZnmwASNTNCBCXoewZvundNFqY8rqV8TnzTpAZzZmSadAddHFbX0Tl6IjNzBXgRbS5R4ft3ycMtp3eiPqb6Q9ghedMP0JsXE1X5yjjRZliZUzRaneLQQjG7dqUgk1WWKQC6JTEdAVcWXR-rjo1BdnOoKqEJG8LYVrotl_X87Nq_-iuewgadVfx4e7j-BWwmlkITfWFuwPjs7908R2M3ss3CCGPy87iP7D0HzXsM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Understanding+COVID-19+vaccine+hesitancy+and+resistance%3A+another+challenge+in+cancer+patients&rft.jtitle=Supportive+care+in+cancer&rft.au=Mejri%2C+Nesrine&rft.au=Berrazega%2C+Yosra&rft.au=Ouertani%2C+Emna&rft.au=Rachdi%2C+Haifa&rft.date=2022-01-01&rft.eissn=1433-7339&rft.volume=30&rft.issue=1&rft.spage=289&rft_id=info:doi/10.1007%2Fs00520-021-06419-y&rft_id=info%3Apmid%2F34279721&rft.externalDocID=34279721 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0941-4355&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0941-4355&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0941-4355&client=summon |